Feline leukemia virus (FeLV) is a retrovirus of cats worldwide. High viral loads are associated with progressive infection and the host's death from FeLV-associated disease.
By contrast, cats with regressive infection may show a low viral load, an effective immune response, and a better clinical outcome. We believe that by reducing the viral load in progressively infected cats using gene therapy supported by CRISPR / SaCas9, the cat's immune system may be able to shift the infection toward a regressive outcome.
To date, no treatment regimen is known that reliably cures progressive FeLV infection in cats or other retroviral infections. Therefore, new therapeutic classes are being developed, including the study and application of gene therapy. Adeno-associated viral vectors (AAV) represent the only chance to save sick cats.
Gene editing technology and target selection.
The recently developed CRISPR/SaCas9 gene editing technology has been used to explore its potential to excise selected target regions in the FeLV provirus.
The CRISPR / SaCas9 adeno-associated vector system reduces feline leukemia virus production in vitro
Your support works real miracles:
How we help:
✓ We pay for the treatment of seriously ill cats with leukemiaFOUNDATION DOCUMENTS
Registration documents Annual reports Press releases Registration documents